Phillip Md Et Al Frost Acquires 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00. Following the completion of the purchase, the chief executive officer now owns 211,712,405 shares in the company, valued at approximately $336,622,723.95. This trade represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were purchased at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Up 1.3 %

Shares of NASDAQ:OPK opened at $1.58 on Friday. The stock has a market capitalization of $1.08 billion, a PE ratio of -8.32 and a beta of 1.65. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The firm has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.44. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently bought and sold shares of OPK. Rubric Capital Management LP boosted its holdings in OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd bought a new stake in OPKO Health during the second quarter valued at about $1,840,000. Assenagon Asset Management S.A. boosted its holdings in OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Clearline Capital LP bought a new stake in OPKO Health during the third quarter valued at about $1,083,000. Finally, Squarepoint Ops LLC bought a new stake in OPKO Health during the second quarter valued at about $592,000. 64.63% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on OPK. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.